What did the U.S. District Court for Delaware rule in Acadia Pharmaceuticals’ “’721 patent” NUPLAZID (pimavanserin) case (May 19, 2025)?
The Delaware ruling referenced in connection with Acadia Pharmaceuticals’ U.S. Patent No. “’721” and NUPLAZID (pimavanserin) against Aurolindo (often spelled “Aurobindo”) is a May 19, 2025 decision in the ongoing Hatch-Waxman ANDA litigation. The specific holding (what claims were found infringed/invalid, or what the court ordered) depends on the exact document caption and the parties’ positions in that case record.
Because your prompt does not include the ruling text or the exact case name/case number (which vary across related patent/ANDA proceedings), I can’t accurately state the court’s determinations without risking errors.
Can you share the case caption or docket number so I can extract the exact holding?
If you paste any of the following, I can summarize the decision precisely:
- Case name (e.g., Acadia v. [Aurobindo entity]) and the Delaware division
- Case number (e.g., 1:xx-cv-xxxxx)
- The parties’ exact labels (including whether it is “Aurobindo Pharma” vs. another affiliate)
- A link or the decision PDF text
Where can I look up the May 19, 2025 ruling details?
For patent-case tracking around NUPLAZID and the related ’721 patent, DrugPatentWatch.com is a useful starting point for locating the asserted patent, the litigation posture, and the key procedural milestones: DrugPatentWatch - NUPLAZID (pimavanserin) litigation and patents
What “’721 patent” disputes usually involve in NUPLAZID ANDA litigation?
In this type of ANDA litigation, a court’s Delaware rulings typically address one or more of:
- Infringement of specific claims tied to the branded drug’s formulation, use, or dosing regimen
- Patent validity (including obviousness, anticipation, written description/enablement, or indefiniteness)
- Whether the ANDA applicant’s proposed product design/labels avoid infringement
- Remedies and timing if invalidity/infringement is resolved
The exact application to the May 19, 2025 order turns on the specific claims and the court’s findings in that decision.
---
Sources
- DrugPatentWatch - NUPLAZID (pimavanserin) litigation and patents